CorMedix Inc.

NasdaqGM:CRMD Stock Report

Market Cap: US$921.1m

CorMedix Future Growth

Future criteria checks 5/6

CorMedix is forecast to grow earnings and revenue by 33.8% and 24.9% per annum respectively while EPS is expected to grow by 30.7% per annum.

Key information

33.8%

Earnings growth rate

30.66%

EPS growth rate

Pharmaceuticals earnings growth14.6%
Revenue growth rate24.9%
Future return on equityn/a
Analyst coverage

Good

Last updated20 Jun 2025

Recent future growth updates

Recent updates

CorMedix: Exceeding Expectations

Jun 04
author-image

DefenCath Launch Will Boost Inpatient And Dialysis Opportunities

Strong revenue growth prospects from DefenCath's successful launch and expansion into new segments like inpatient facilities and partnerships.

The Hidden Risks Behind CorMedix's First Profitable Quarter

Mar 26

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jan 17
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix: Finally In Commercialization Mode

Jan 07

CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Dec 13
CorMedix Inc.'s (NASDAQ:CRMD) P/S Is On The Mark

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Earnings and Revenue Growth Forecasts

NasdaqGM:CRMD - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20272621441381384
12/31/202621310381796
12/31/20251455690906
3/31/20258317-14-14N/A
12/31/202443-18-51-51N/A
9/30/202412-46-56-56N/A
6/30/20241-53-51-51N/A
3/31/2024N/A-50-46-45N/A
12/31/2023N/A-46-39-38N/A
9/30/20230-40-34-34N/A
6/30/20230-37-31-31N/A
3/31/20230-33-28-28N/A
12/31/20220-30-25-24N/A
9/30/20220-29-25-24N/A
6/30/20220-31-25-24N/A
3/31/20220-28-23-21N/A
12/31/20210-28-23-21N/A
9/30/20210-27-22-21N/A
6/30/20210-25-23-23N/A
3/31/20210-24-21-21N/A
12/31/20200-22-22-22N/A
9/30/20200-21-20-20N/A
6/30/20200-47-17-17N/A
3/31/20200-44-16-16N/A
12/31/20190-44-15-15N/A
9/30/20190-36-18-18N/A
6/30/20191-14-20-20N/A
3/31/20191-22-24-24N/A
12/31/20180-27N/A-24N/A
9/30/20180-39N/A-24N/A
6/30/20180-39N/A-25N/A
3/31/20180-36N/A-29N/A
12/31/20170-33N/A-29N/A
9/30/20170-29N/A-28N/A
6/30/20170-28N/A-28N/A
3/31/20170-28N/A-24N/A
12/31/20160-25N/A-22N/A
9/30/20160-22N/A-19N/A
6/30/20160-18N/A-16N/A
3/31/20160-17N/A-16N/A
12/31/20150-18N/A-13N/A
9/30/20150-17N/A-10N/A
6/30/20150-17N/A-9N/A
3/31/20150-9N/A-7N/A
12/31/20140-21N/A-6N/A
9/30/20140-22N/A-6N/A
6/30/20140-19N/A-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: CRMD's forecast earnings growth (33.8% per year) is above the savings rate (2.9%).

Earnings vs Market: CRMD's earnings (33.8% per year) are forecast to grow faster than the US market (14.6% per year).

High Growth Earnings: CRMD's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: CRMD's revenue (24.9% per year) is forecast to grow faster than the US market (8.7% per year).

High Growth Revenue: CRMD's revenue (24.9% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if CRMD's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/20 16:23
End of Day Share Price 2025/06/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CorMedix Inc. is covered by 20 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Andrew D'SilvaB. Riley Securities, Inc.
Jason ButlerCitizens JMP Securities, LLC
Jason KolbertD. Boral Capital LLC.